Fluvoxamine to Treat COVID-19?

The TOGETHER Study, published in Lancet, evaluated the role of fluvoxamine in the treatment of COVID-19. Is this a real GameChanger, or just another dud? Lay media has been picking up the study - listen to Geoff and Jake break down the article to help healthcare providers give evidence-based recommendations.GuestJohn A Galdo, PharmD, MBA, BCPS, BCGPCourse Content and Developer, CEimpactPharmacist, Ross Bridge PharmacyCEO, SeguridadRedeem your CPE or CME credit here! Claim CPE CreditClaim CME CreditNeed a membership?Join for CPE CreditJoin for CME CreditReferences and resources: Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021 Oct 27:S2214-109X(21)00448-4. doi: 10.1016/S2214-109X(21)00448-4. Epub ahead of print. PMID: 34717820; PMCID: PMC8550952.Additional Resources:WSJ Opinion on FluvoxamineWSJ Letter-to-EditorContinuing Education Information:Learning Objectives: 1. Describe the inclusion and exclusion criteria for the TOGETHER study2. Discuss the role of Drug-Drug Interactions with fluvoxamine0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-21-394-H01-PInitial release date: 11/15/21Expiration date: 11/15/22Dr. Galdo reports that he is on a speaker's bureau for Novo Nordisk.Complete CPE & CME details can be found hereFollow CEimpact on Social Media:LinkedInInstagram